Eliad Culcea, MD
Neurology · Great Falls, MTNPI 1831172816
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Acorda Therapeutics, Inc at 46.0% of the total. Reporting peaked in 2019 at $8,962 and has fallen 58.2% since, to $3,749 in 2025.
Across 439 payments — averaging $43.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acorda Therapeutics, Inc$9K
- Boston Scientific$2K
- AbbVie$1K
- Medtronic$1K
- Bristol Myers Squibb$666
- Teva Pharmaceuticals USA, Inc.$581
- plus $4K from 40 others
What the payments were for
- Speaking & faculty fees$8,04242%
- Travel & lodging$3,31617%
- Food & beverage$7,58740%
- Education$1961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,142 in reported general payments places this provider in the 85th percentile of 48 neurology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 32 | $877,188 |
| CopaxoneGlatiramer Acetate | 55 | $349,628 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 53 | $338,204 |
| RebifInterferon Beta-1a/Albumin | 13 | $134,321 |
| Kesimpta PenOfatumumab | 14 | $119,467 |
| RytaryCarbidopa/Levodopa | 46 | $66,875 |
| NuplazidPimavanserin Tartrate | 12 | $55,112 |
| QuliptaAtogepant | 29 | $36,571 |
| Emgality PenGalcanezumab-Gnlm | 34 | $35,536 |
| KeppraLevetiracetam | 11 | $31,357 |
| XcopriCenobamate | 16 | $27,862 |
| RexultiBrexpiprazole | 12 | $14,059 |
| Lacosamide | 188 | $13,150 |
| Felbamate | 65 | $10,348 |
| LyricaPregabalin | 12 | $8,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Evrysdi | $225 | $877,18832 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $581 | $349,62855 claims |
| Grifols USA, LLCGamunex-C | $64 | $338,20453 claims |
| EMD Serono, Inc.Rebif | $180 | $134,32113 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide | $146 | $75,725137 claims |
| Acadia Pharmaceuticals IncNuplazid | $115 | $55,11212 claims |
| AbbVieQulipta | $1,286 | $36,57129 claims |
| SK Life Science, Inc.Xcopri | $95 | $27,86216 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $17 | $14,05912 claims |
| PfizerLyrica, Dilantin | $44 | $11,32323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 neurology providers in Montana.
Other neurology in Great Falls
- Dennis DietrichGreat Falls$140K
- Deborah DoverGreat Falls$19K
- Walter Lajara-NansonGreat Falls$6K
- William HenningGreat Falls$4K
- Cody SandersGreat Falls$1K
- Ann CollierBillings$164K
- Nicole ClarkHelena$85K
- Kristian FrenchBillings$64K
- Norman FriedmanKalispell$35K
- Emily PharrBozeman$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.